Instrument Inactif

Autres langues Checkmate Pharmaceuticals, Inc.

Actions

CMPI

US1628181083

Recherche biotechnologique et médicale

Autres langues

02/06/22	Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences
02/06/22	Kuros erhält durch Checkmate-Übernahme Meilensteinzahlung von 5 Mio USD
02/06/22	Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate
02/06/22	Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
31/05/22	Checkmate Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K
31/05/22	CHECKMATE PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
31/05/22	Checkmate Pharmaceuticals, Inc. Appoints Robert E. Landry as Chief Financial Officer
31/05/22	Checkmate Pharmaceuticals, Inc. Announces Board Changes
31/05/22	Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from NASDAQ Composite Index
31/05/22	Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from S&P TMI Index
27/05/22	Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.
26/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
26/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting
26/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
17/05/22	CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI
12/05/22	CHECKMATE PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
12/05/22	Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
12/05/22	Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
12/05/22	Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
06/05/22	CHECKMATE PHARMACEUTICALS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI
27/04/22	Kuros Biosciences' Q1 Medical Devices Sales Surge 102% Following US FDA Approval For MagnetOs
19/04/22	Checkmate Pharmaceuticals : TENDER AND SUPPORT AGREEMENT - Form 8-K
19/04/22	CHECKMATE PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
19/04/22	Sector Update: Health Care Stocks Carried Higher in Rising Tuesday Markets
19/04/22	Top Midday Gainers